Structure determined for critical SARS enzyme
ARGONNE, Ill. (Sept. 12, 2003) — Moving one step closer in the battle
against Severe Acute Respiratory Syndrome (SARS), researchers from a California
company using the powerful X-rays at the Advanced
Photon Source have determined the first structure of the main protease
from the coronavirus that causes SARS. A protease is a viral enzyme
critical in the SARS life cycle.
The scientists from Structural GenomiX created a
three-dimensional, high-resolution image of a crystal of the SARS virus, which
will be useful to researchers developing a drug to inhibit the SARS virus
replication. A similar strategy succeeded with the human immunodeficiency virus
protease for treatment of AIDS.
Structural GenomiX is a San Diego, Calif., -based company that
operates a macromolecular X-ray diffraction beamline at the APS, located at the
U.S. Department of Energy's Argonne National Laboratory. The APS is this
hemisphere's most brilliant source of X-rays for research. The company uses the
X-rays to reveal in atomic detail how small molecules interact with drug
targets in structure-guided drug design.
Because of the serious public health issue posed by SARS,
Structural GenomiX deposited the crystal structure in the Protein Data Bank, a
public database available to researchers worldwide, before publishing a paper
in a refereed scientific journal. The company is exploring collaborative
opportunities to develop a treatment.
With the experimental structure and an ample supply of crystals of
the SARS main protease in hand, the company can now conduct experiments to
determine the structure of the site where the protease creates infectious
particles the protease-inhibitor complex and to create a drug
molecule that fits in the active site to block this step.
Structural GenomiX used its proprietary process to create the
crystal and the company's X-ray data collection facility at the APS to
determine the protease's crystal structure at a resolution of 1.86 Angstroms
less than one atom's width.
They determined the crystal structure in a little more than one
month after receiving cDNA clones from the
Genome Institute of
Singapore. The typical timeframe for this is usually months or years.
"SARS has been labeled the first '21st century epidemic'," said
Joshua Lederberg, Ph.D., President Emeritus of
The Rockefeller University, Nobel
Laureate, and a leading expert in antiviral research.
Structural GenomiX is setting an example by sharing this structure
with the research world to speed drug development in case SARS recurs,
Lederberg said.
Argonne National Laboratory seeks solutions to pressing national problems in science and technology.
The nation's first national laboratory, Argonne conducts leading-edge basic
and applied scientific research in virtually every scientific discipline. Argonne
researchers work closely with researchers from hundreds of companies, universities,
and federal, state and municipal agencies to help them solve their specific
problems, advance America 's scientific leadership and prepare the nation for
a better future. With employees from more than 60 nations, Argonne is managed
by UChicago
Argonne, LLC for
the U.S.
Department of Energy's Office
of Science.
For more information, please
contact Steve McGregor (630/252-5580 or media@anl.gov)
at Argonne.
|